Trials / Sponsors / Replicor Inc.
Replicor Inc.
Industry · 7 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Completed | A Long Term Follow-up Study of Patients From the REP 301 Protocol Hepatitis B, Chronic, Hepatitis D, Chronic | — | 2016-08-01 |
| Completed | REP 2139-Mg and REP 2165-Mg Combination Therapy in Chronic Hepatitis B Infection Chronic Hepatitis B | Phase 2 | 2016-03-01 |
| Completed | REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infection Chronic HBV Infection (HBeAg Negative) | Phase 2 | 2014-09-01 |
| Completed | Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B Hepatitis B, Chronic | Phase 2 | 2012-10-01 |
| Completed | Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients Hepatitis B, Chronic | Phase 1 / Phase 2 | 2011-08-01 |
| Completed | Therapeutic Safety and Efficacy of REP 9AC (REP 2055) in HBV or HCV Infected Patients Hepatitis B, Chronic | Phase 1 / Phase 2 | 2009-01-01 |
| No Longer Available | Replicor Compassionate Access Program Viral Hepatitis B, Viral Hepatitis D, Cirrhosis, Liver | — | — |